Precision BioSciences Inc. (NASDAQ:DTIL) shares traded 9.23% higher at $0.64 on Wall Street last session.
In accordance with the data, 6 analysts cover Precision BioSciences Inc. (NASDAQ:DTIL). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $17.00 and a low of $1.00, we find $5.00. Given the previous closing price of $0.59, this indicates a potential upside of 747.46 percent. DTIL stock price is now -11.26% away from the 50-day moving average and -39.69% away from the 200-day moving average. The market capitalization of the company currently stands at $66.84M.
It has been rated a hold by 2 analysts and a buy by 4. Brokers who have rated the stock have averaged $6.50 as their price target over the next twelve months.
With the price target of $7, BMO Capital Markets recently initiated with Outperform rating for Precision BioSciences Inc. (NASDAQ: DTIL).
In other news, Scimeca Dario, General Counsel and Secretary sold 13,361 shares of the company’s stock on Jun 08. The stock was sold for $10,021 at an average price of $0.75. Upon completion of the transaction, the General Counsel and Secretary now directly owns 68,473 shares in the company, valued at $43822.72. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 27, Chief Medical Officer List Alan sold 7,771 shares of the business’s stock. A total of $6,139 was realized by selling the stock at an average price of $0.79. This leaves the insider owning 56,496 shares of the company worth $36157.44. Insiders disposed of 87,421 shares of company stock worth roughly $55949.44 over the past 1 year. A total of 1.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DTIL stock. A new stake in Precision BioSciences Inc. shares was purchased by JACOBS LEVY EQUITY MANAGEMENT, INC during the first quarter worth $504,000. BANK OF MONTREAL /CAN/ invested $191,000 in shares of DTIL during the first quarter. In the first quarter, LANDSCAPE CAPITAL MANAGEMENT, L.L.C. acquired a new stake in Precision BioSciences Inc. valued at approximately $65,000. CITIGROUP INC acquired a new stake in DTIL for approximately $30,000. DARK FOREST CAPITAL MANAGEMENT LP purchased a new stake in DTIL valued at around $12,000 in the second quarter. In total, there are 134 active investors with 47.40% ownership of the company’s stock.
Precision BioSciences Inc. (NASDAQ: DTIL) opened at $0.5880 on Monday. During the past 12 months, Precision BioSciences Inc. has had a low of $0.51 and a high of $2.12. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.60, and a quick ratio of 3.60. The fifty day moving average price for DTIL is $0.7178 and a two-hundred day moving average price translates $1.0573 for the stock.
The latest earnings results from Precision BioSciences Inc. (NASDAQ: DTIL) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.23, inline with analysts’ expectations of -$0.23. This compares to -$0.46 EPS in the same period last year. The company reported revenue of $8.78 million for the quarter, compared to $3.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 164.7 percent. For the current quarter, analysts expect DTIL to generate $6.38M in revenue.
Precision BioSciences Inc.(DTIL) Company Profile
Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
